Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma

NCT00026416 is registered in ClinicalTrials.gov with Herbert Irving Comprehensive Cancer Center as lead sponsor.

NCT NCT00026416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00026416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma